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Abstract
The human microbiome is increasingly mined for diagnostic and therapeutic
biomarkers using machine learning (ML). However, metagenomics-specific software is
scarce, and overoptimistic evaluation and limited cross-study generalization are
prevailing issues. To address these, we developed SIAMCAT, a versatile R toolbox for
ML-based comparative metagenomics. We demonstrate its capabilities in a meta-
analysis of fecal metagenomic studies (10,803 samples). When naively transferred across
studies, ML models lost accuracy and disease specificity, which could however be
resolved by a novel training set augmentation strategy. This reveals some biomarkers to
be disease-specific, with others shared across multiple conditions. SIAMCAT is freely
available from siamcat.embl.de.
Keywords: Microbiome data analysis, Machine learning, Statistical modeling,
Microbiome-wide association studies (MWAS), Meta-analysis
Introduction
The study of microbial communities through metagenomic sequencing has begun to
uncover how communities are shaped by—and interact with—their environment, in-
cluding the host organism in the case of gut microbes [1, 2]. Especially within a disease
context, differences in human gut microbiome compositions have been linked to many
common disorders, for example, colorectal cancer [3], inflammatory bowel disease [4,
5], or arthritis [6, 7]. As the microbiome is increasingly recognized as an important fac-
tor in health and disease, many possibilities for clinical applications are emerging for
diagnosis [8, 9], prognosis, or prevention of disease [10].
The prospect of clinical applications also comes with an urgent need for methodo-
logical rigor in microbiome analyses in order to ensure the robustness of findings. It is
necessary to assess the clinical value of biomarkers identified from the microbiome in
an unbiased manner—not only by their statistical significance, but more importantly
also by their prediction accuracy on independent samples (allowing for external
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validation). Machine learning (ML) models—ideally interpretable and parsimonious
ones—are crucial tools to identify and validate such microbiome signatures. Setting up
ML workflows however poses difficulties for novices. In general, it is challenging to as-
sess their performance in an unbiased way, to apply them in cross-study comparisons,
and to avoid confounding factors, for example, when disease and treatment effects are
intertwined [11]. For microbiome studies, additional issues arise from key characteris-
tics of metagenomic data such as large technical and inter-individual variation [12],
experimental bias [13], compositionality of relative abundances, zero inflation, and
non-Gaussian distribution, all of which necessitate data normalization in order for ML
algorithms to work well.
While several statistical analysis tools have been developed specifically for micro-
biome data, they are generally limited to testing for differential abundance of microbial
taxa between groups of samples and do not allow users to evaluate their predictivity as
they do not comprise full ML workflows for biomarker discovery [14–16]. To overcome
the limitations of testing-based approaches, several researchers have explicitly built ML
classifiers to distinguish case and control samples [17–24]; however, the software
resulting from these studies is generally not easily modified or transferred to other clas-
sification tasks or data types. To our knowledge, a powerful yet user-friendly computa-
tional ML toolkit tailored to the characteristics of microbiome data has not yet been
published.
Here, we present SIAMCAT (Statistical Inference of Associations between Microbial
Communities And host phenoTypes), a comprehensive toolbox for comparative meta-
genome analysis using ML, statistical modeling, and advanced visualization approaches.
It also includes functionality to identify and visually explore confounding factors. To
demonstrate its versatile applications, we conducted a large-scale ML meta-analysis of
130 classification tasks from 50 gut metagenomic studies (see Table 1) that have been
processed with a diverse set of taxonomic and functional profiling tools. Based on this
large-scale application, we arrive at recommendations for sensible parameter choices
for the ML algorithms and preprocessing strategies provided in SIAMCAT. Moreover,
we illustrate how several common pitfalls of ML applications can be avoided using the
statistically rigorous approaches implemented in SIAMCAT. When considering the
cross-study application of ML models, we note prevailing problems with type I error
control (i.e., elevated false-positive rate, abbreviated as FPR) as well as disease specifi-
city for ML models naively transferred across datasets. To alleviate these issues, we
propose a strategy based on sampling additional external controls during cross-
validation (which we call control augmentation). This enables cross-disease comparison
of gut microbial biomarkers. Lastly, we showcase how SIAMCAT facilitates meta-
analyses in an application to fecal shotgun metagenomic data from five independent
studies of Crohn’s disease. SIAMCAT is implemented in the R programming language
and freely available from siamcat.embl.de or Bioconductor.
Results
Machine learning and statistical analysis workflows implemented in SIAMCAT
The SIAMCAT R package is a versatile toolbox for analyzing microbiome data from
case-control studies. The default workflows abstract from and combine many of the
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complex steps that these workflows entail and that can be difficult to implement cor-
rectly for non-experts. To increase ease of use, SIAMCAT interfaces with the popular
phyloseq package [69], and design and parameter choices are carefully adapted to meta-
genomic data analysis. In addition to functions for statistical testing of associations,
SIAMCAT workflows include ML procedures, also encompassing data preprocessing,
model fitting, performance evaluation, and visualization of the results and models
(Fig. 1a). Core ML functionality is based on the mlr package [70]. The input for
SIAMCAT consists of a feature matrix (abundances of microbial taxa, genes, or path-
ways across all samples), a group label (case-control information for all samples), and
optional meta-variables (such as demographics, lifestyle, and clinical records of sample
donors or technical parameters of data acquisition).
To demonstrate the main workflow and primary outputs of the SIAMCAT package
(see the “Methods” section and SIAMCAT vignettes), we analyzed a representative
dataset [27] consisting of 128 fecal metagenomes from patients with ulcerative colitis
(UC) and non-UC controls (Fig. 1). UC is a subtype of inflammatory bowel disease
Table 1 Overview of diseases and datasets included in the ML meta-analysis
Disease Disease abbr. Datasets Data type
Ankylosing spondylitis AS [7] Shotgun
Rheumatoid arthritis ART [25] 16S rRNA
[6] Shotgun
Type 1 diabetes T1D [26] 16S rRNA
Crohn’s disease CD [5, 27–30] Shotgun
Ulcerative colitis UC [5, 27, 30] Shotgun
Inflammatory bowel disease IBD [4, 31–33] 16S rRNA
Colorectal cancer CRC [8, 34–39] Shotgun
[8, 40–42] 16S rRNA
Advanced colorectal adenoma(s) ADA [8, 34, 38, 39] Shotgun






Clostridioides difficile infection CDI [45, 46] 16S rRNA
Enteric diarrheal disease EDD [47] 16S rRNA
HIV infection HIV [48–50] 16S rRNA
Liver cirrhosis LIV [51] Shotgun
[52] 16S rRNA
Non-alcoholic fatty liver disease NAFLD [53, 54] Shotgun
[55, 56] 16S rRNA
Parkinson’s disease PAR [57] Shotgun
[58] 16S rRNA
Autism spectrum disorder ASD [59, 60] 16S rRNA
Obesity OB [61] Shotgun
[62–65] 16S rRNA
Metabolic syndrome MS [66] Shotgun
Type 2 diabetes T2D [67, 68] Shotgun
Impaired glucose tolerance IGT [67] Shotgun
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Fig. 1 SIAMCAT statistical and machine learning approach model differences between the groups of
microbiome samples. a Each step in the SIAMCAT workflow (green boxes) is implemented by a function in
the R/Bioconductor package (see SIAMCAT vignettes). Functions producing graphical output (red boxes) are
illustrated in b–e for an exemplary analysis using a dataset from Nielsen et al. [27] which contains ulcerative
colitis (UC) patients and non-UC controls. b Visualization of the univariate association testing results. The left
panel visualizes the distributions of microbial abundance data differing significantly between the groups.
Significance (after multiple testing correction) is displayed in the middle panel as horizontal bars. The right
panel shows the generalized fold change as a non-parametric measure of effect size [37]. c SIAMCAT offers
statistical tests and diagnostic visualizations to identify potential confounders by testing for associations
between such meta-variables as covariates and the disease label. The example shows a comparison of body
mass index (BMI) between the study groups. The similar distributions between cases and controls suggest
that BMI is unlikely to confound UC associations in this dataset. Boxes denote the IQR across all values with
the median as a thick black line and the whiskers extending up to the most extreme points within 1.5-fold
IQR. d The model evaluation function displays the cross-validation error as a receiver operating
characteristic (ROC) curve, with a 95% confidence interval shaded in gray and the area under the receiver
operating characteristic curve (AUROC) given below the curve. e SIAMCAT finally generates visualizations
aiming to facilitate the interpretation of the machine learning models and their classification performance.
This includes a barplot of feature importance (in the case of penalized logistic regression models, bar width
corresponds to coefficient values) for the features that are included in the majority of models fitted during
cross-validation (percentages indicate the respective fraction of models containing a feature). A heatmap
displays their normalized values across all samples (as used for model fitting) along with the classification
result (test predictions) and user-defined meta-variables (bottom)
Wirbel et al. Genome Biology           (2021) 22:93 Page 4 of 27
(IBD), a chronic inflammatory condition of the gastrointestinal tract that has been asso-
ciated with dramatic changes in the gut microbiome [5, 71]. As input, we used species-
level taxonomic profiles available through the curatedMetagenomicsData R package [72].
After data preprocessing (unsupervised abundance and prevalence filtering, Fig. 1a
and the “Methods” section), univariate associations of single species with the disease
are computed using the non-parametric Wilcoxon test (which has been shown for
metagenomic data to reliably control the false discovery rate in contrast to many other
tests proposed [73]), and the results are visualized (using the check.associations func-
tion). The association plot displays the distribution of microbial relative abundance, the
significance of the association, and a generalized fold change as a non-parametric meas-
ure of effect size [37] (Fig. 1b).
The central component of SIAMCAT consists of ML procedures, which include a se-
lection of normalization methods (normalize.features), functionality to set up a cross-
validation scheme (create.data.split), and interfaces to different ML algorithms, such as
LASSO, Elastic Net, and random forest (offered by the mlr package [70]) [74–76]. As
part of the cross-validation procedure, models can be trained (train.model) and applied
to make predictions (make.predictions) on samples not used for training. Based on
these predictions, the performance of the model is assessed (evaluate.predictions) using
the area under the receiver operating characteristic (ROC) curve (AUROC) (Fig. 1d).
SIAMCAT also provides diagnostic plots for the interpretation of ML models
(model.interpretation.plot) which display the importance of individual features in the
classification model, normalized feature distributions as heatmaps, next to sample
meta-variables (optionally, see Fig. 1c, e).
Expert users can readily customize and flexibly recombine the individual steps in the de-
scribed workflow above. For example, filtering and normalization functions can be com-
bined or omitted before ML models are trained or association statistics calculated. To
demonstrate its versatility beyond the workflow presented in Fig. 1a, we used SIAMCAT
to reproduce two recent ML meta-analyses of metagenomic datasets [19, 20]. By imple-
menting the same workflows as described in the respective papers, we could generate
models with very similar accuracy (within the 95% confidence interval) for all datasets an-
alyzed (Additional file 1: Figure S1).
Confounder analysis using SIAMCAT
As many biological and technical factors beyond the primary phenotype of interest
can influence microbiome composition [1], microbiome association studies are
often at a high risk of confounding, which can lead to spurious results [11, 77–79].
To minimize this risk, SIAMCAT provides a function to optionally examine poten-
tial confounders among the provided meta-variables. In the example dataset from [27],
control samples were obtained from both Spanish and Danish subjects, while UC samples
were only taken from Spanish individuals (Fig. 2a). Here, the meta-variable “country” could
be viewed as a surrogate variable for other (often difficult-to-measure) factors, which can in-
fluence microbiome composition, such as diet, lifestyle, or technical differences between
studies. The strong association of the “country” meta-variable with the disease status (SIAM
CAT computes such associations using Fisher’s exact test or the Wilcoxon test for discrete
and continuous meta-variables, respectively; see Fig. 2a) hints at the possibility that
Wirbel et al. Genome Biology           (2021) 22:93 Page 5 of 27
associations computed with the full dataset could be confounded by the country of the
sample donor.
To quantify this confounding effect on individual microbial features, SIAMCAT add-
itionally provides a plot for each meta-variable that shows the variance explained by
the label in comparison with the variance explained by the meta-variable for each indi-
vidual feature (Fig. 2b, implemented in the check.confounder function). In our example
case, several microbial species are strongly associated with both the disease phenotype
(UC vs control) and the country, indicating that their association with the label might
simply be an effect of technical and/or biological differences between samples taken
and data processed in the different countries.
Fig. 2 Analysis of covariates that potentially confound microbiome-disease associations and classification
models. The UC dataset from Nielsen et al. [27] contains fecal metagenomes from subjects enrolled in two
different countries and generated using different experimental protocols (data shown is from
curatedMetagenomicData with CD cases and additional samples per subject removed). a Visualizations from
the SIAMCAT confounder checks reveals that only control samples were taken from Denmark suggesting
that any (biological or technical) differences between Danish and Spanish samples might confound a naive
analysis for UC-associated differences in microbial abundances. b Analysis of variance (using ranked
abundance data) shows many species differ more by country than by disease, with several extreme cases
highlighted. c When comparing (FDR-corrected) P values obtained from SIAMCAT’s association testing
function applied to the whole dataset (y-axis) to those obtained for just the Danish samples (x-axis), only a
very weak correlation is seen and strong confounding becomes apparent for several species including
Dorea formicigenerans (highlighted). d Relative abundance differences for Dorea formicigenerans are
significantly larger between countries than between Spanish UC cases and controls (P values from Wilcoxon
test) (see Fig. 1c for the definition of boxplots). e Distinguishing UC patients from controls with the same
workflow is possible with lower accuracy when only samples from Spain are used compared to the full
dataset containing Danish and Spanish controls. This implies that in the latter case, the machine learning
model is confounded as it exploits the (stronger) country differences (see c and f), not only UC-associated
microbiome changes. f This is confirmed by the result that control samples from Denmark and Spain can
be very accurately distinguished with an AUROC of 0.96 (using SIAMCAT classification workflows)
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To further investigate this confounder, we used SIAMCAT to compute statistical as-
sociation for the full dataset (including the Danish control samples) and the reduced
dataset containing only samples from Spanish individuals (using the check.association
function). The finding that P values were uncorrelated between the two datasets (Fig.
2c) directly quantified the effect of confounding by country on the disease-association
statistic. The potential severity of this problem is highlighted by a comparison of the
relative abundance of Dorea formicigenerans across subjects: the differences between
UC cases and controls are only significant when Danish control samples are included,
but not when restricted to Spanish samples only (Fig. 2d), exemplifying how
confounders can lead to spurious associations.
Finally, confounding factors can not only bias statistical association tests, but can also
impact the performance of ML models. A model trained to distinguish UC patients
from controls seemingly performs better if the Danish samples are included (AUROC
of 0.84 compared to 0.76 if only using Spanish samples), because the differences be-
tween controls and UC samples are artificially inflated by the differences between
Danish and Spanish samples (Fig. 2e). How these overall differences between samples
taken in different countries can be exploited by ML models can also be directly quanti-
fied using SIAMCAT workflows. The resulting model trained to distinguish between
control samples from the two countries can do so with almost perfect accuracy
(AUROC of 0.96) (Fig. 2f). This analysis demonstrates how confounding factors can
lead to exaggerated performance estimates for ML models.
In summary, SIAMCAT can help to detect influential confounding factors that have
the potential to bias statistical associations and ML model evaluations (see Additional
file 1: Figure S2 for additional examples).
Advanced machine learning workflows
When designing more complex ML workflows involving feature selection steps or ap-
plications to time series data, it becomes more challenging to set up cross-validation
procedures correctly. Specifically, it is important to estimate how well a trained model
would generalize to an independent test set, which is typically the main objective of mi-
crobial biomarker discovery. An incorrect ML procedure, in which information leaks
from the test to the training set, can result in overly optimistic (i.e., overfitted) perform-
ance estimates. Two pitfalls that can lead to overfitting and poor generalization to other
datasets (Fig. 3a) are frequently encountered in ML analyses of microbiome and other
biological data, even though the issues are well described in the statistics literature
[80–82]. These issues, namely supervised feature filtering and naive splitting of
dependent samples, can be exposed by testing model performance in an external valid-
ation set, which has not been used during cross-validation at all (Fig. 3b).
The first issue arises when feature selection taking label information into account (su-
pervised feature selection) is naively combined with subsequent cross-validation on the
same data [81]. This incorrect procedure selects features that are associated with the
label (e.g., by testing for differential abundance) on the complete dataset leaving no data
aside for an unbiased test error estimation of the whole ML procedure. To avoid over-
fitting, correct supervised feature selection should always be nested into cross-
validation (that is, the supervised feature selection has to be applied to each training
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fold of the cross-validation separately). To illustrate the extent of overfitting resulting
from the incorrect approach, we used two datasets of colorectal cancer (CRC) patients
and controls and performed both the incorrect and correct ways of supervised feature
selection. As expected, the incorrect feature selection led to inflated performance esti-
mates in cross-validation but lower generalization to an external dataset, whereas the
correct procedure gave a better estimate of the performance in the external test set; the
fewer features were selected, the more the performance in the external datasets
dropped (see Fig. 3c). SIAMCAT readily provides implementations of the correct pro-
cedure and additionally takes care that the feature filtering and normalization of the
whole dataset are blind to the label (therefore called unsupervised), thereby preventing
accidental implementation of the incorrect procedure.
The second issue tends to occur when samples are not independent [82]. For ex-
ample, microbiome samples taken from the same individual at different time points are
usually a lot more similar to each other than those from different individuals (see [12]
and Additional file 1: Figure S3). If these dependent samples are randomly split in a
standard cross-validation procedure, so that some could end up in the training set and
others in the test set, it is effectively estimated how well the model generalizes across
time points (from the same individual) rather than across individuals. To avoid this,
dependent measurements need to be blocked during cross-validation, ensuring that
Fig. 3 SIAMCAT aids in avoiding common pitfalls leading to a poor generalization of machine learning
models. a Incorrectly setup machine learning workflows can lead to overoptimistic accuracy estimates
(overfitting): the first issue arises from a naive combination of feature selection on the whole dataset and
subsequent cross-validation on the very same data [80]. The second one arises when samples that were not
taken independently (as is the case for replicates or samples taken at multiple time points from the same
subject) are randomly partitioned in cross-validation with the aim to assess the cross-subject generalization
error (see the main text). b External validation, for which SIAMCAT offers analysis workflows, can expose
these issues. The individual steps in the workflow diagram correspond to SIAMCAT functions for fitting a
machine learning model and applying it to an external dataset to assess its external validation accuracy (see
SIAMCAT vignette: holdout testing with SIAMCAT). c External validation shows overfitting to occur when
feature selection and cross-validation are combined incorrectly in a sequential manner, rather than correctly
in a nested approach. The correct approach is characterized by a lower (but unbiased) cross-validation
accuracy, but better generalization accuracy to external datasets (see header for datasets used). The fewer
features are selected, the more pronounced the issue becomes, and in the other extreme case (“all”),
feature selection is effectively switched off. d When dependent observations (here by sampling the same
individuals at multiple time points) are randomly assigned to cross-validation partitions, effectively the
ability of the model to generalize across time points, but not across subjects, is assessed. To correctly
estimate the generalization accuracy across subjects, repeated measurements need to be blocked, all of
them either into the training or test set. Again, the correct procedure shows lower cross-validation
accuracy, but higher external validation accuracy
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measurements of the same individual are assigned to the same test set. How much the
naive procedure can overestimate the performance in cross-validation and underper-
form in external validation compared to the correctly blocked procedure is demon-
strated here using the iHMP dataset, which contains several samples per subject [30].
Although the cross-validation accuracy appears dramatically lower in the correct com-
pared to the naive procedure, generalization to other datasets of the same disease is
higher with the correctly blocked model (Fig. 3d). SIAMCAT offers the possibility to
block the cross-validation according to meta-variables by simply providing an add-
itional argument to the respective function call (see also SIAMCAT vignettes).
Large-scale machine learning meta-analysis
Previous studies that applied ML to microbiome data [17–20] have compared and dis-
cussed the performance of several learning algorithms. However, their recommenda-
tions were based on the analysis of a small number of datasets which were technically
relatively homogeneous. To overcome this limitation and to demonstrate that
SIAMCAT can readily be applied to various types of input data, we performed a large-
scale ML meta-analysis of case-control gut metagenomic datasets. We included taxo-
nomic profiles obtained with the RDP taxonomic classifier [83] for 26 datasets based
on 16S rRNA gene sequencing [20]; additionally, taxonomic profiles generated from 12
and 24 shotgun metagenomic datasets using either MetaPhlAn2 [84] or mOTUs2 [85],
respectively, as well as functional profiles obtained with HUMAnN2 [86] or with
eggNOG 4.5 [87] for the same set of shotgun metagenomic data were included (in total
130 classification tasks, see Table 1 and Additional file 2: Table S1 for information
about included datasets).
Focusing first on intra-study results, we found that given a sufficiently large input
dataset (with at least 100 samples), SIAMCAT models are generally able to distinguish
reasonably well between cases and controls: the majority (58%) of these datasets in our
analysis could be classified with an AUROC of 0.75 or higher—compared to only 36%
of datasets with fewer than 100 samples (Fig. 4a–c, Additional file 1: Figures S4 and S5
and the “Methods” section). Of note, accurate ML-based classification was possible
even for datasets in which cases and controls could not easily be separated using beta-
diversity analyses (Additional file 1: Figure S6), indicating that a lack of separation in
ordination analysis does not preclude ML-based workflows to extract accurate micro-
biome signatures. In the datasets for which a direct comparison of mOTUs2 and
MetaPhlAn2 profiles was possible, we did not find any consistent trend towards either
profiling method (paired Wilcoxon P = 0.41, see Additional file 1: Figure S7). When
comparing taxonomic and functional profiles derived from the same dataset, we found
a high correlation between AUROC values (Pearson’s r = 0.92, P < 2 × 10−16), although
on average taxonomic profiles performed slightly better than functional profiles
(Additional file 1: Figure S7). Taken together, this indicates that SIAMCAT can extract
accurate microbiome signatures (model cross-validation AUROC > 0.75 in 64 of 130
classification tasks) from a range of different input profiles commonly used in micro-
biome research.
SIAMCAT provides various methods for data filtering and normalization and inter-
faces to several ML algorithms through mlr [70]. This made it easy to explore the space
Wirbel et al. Genome Biology           (2021) 22:93 Page 9 of 27
Fig. 4 Large-scale application of the SIAMCAT machine learning workflow to human gut metagenomic
disease association studies. a Application of SIAMCAT machine learning workflows to taxonomic profiles
generated from fecal shotgun metagenomes using the mOTUs2 profiler. Cross-validation performance for
discriminating between diseased patients and controls quantified by the area under the ROC curve
(AUROC) is indicated by diamonds (95% confidence intervals denoted by horizontal lines) with sample size
per dataset given as additional panel (cut at N = 250 and given by numbers instead) (see Table 1 and
Additional file 2: Table S1 for information about the included datasets and key for disease abbreviations).
b Application of SIAMCAT machine learning workflows to functional profiles generated with eggNOG 4.5
for the same datasets as in a (see Additional file 1: Figure S4, S7 for additional types of and comparison
between taxonomic and functional input data). c Cross-validation accuracy of SIAMCAT machine learning
workflows as applied to 16S rRNA gene amplicon data for human gut microbiome case-control studies [20]
(see a for definitions). d Influence of different parameter choices on the resulting classification accuracy.
After training a linear model to predict the AUROC values for each classification task, the variance explained
by each parameter was assessed using an ANOVA (see the “Methods” section) (see Fig. 1 for the definition
of boxplots). e Performance comparison of machine learning algorithms on gut microbial disease
association studies. For each machine learning algorithm, the best AUROC values for each task are shown
as boxplots (defined as in d). Generally, the choice of algorithm only has a small effect on classification
accuracy, but both the Elastic Net and LASSO performance gains are statistically significant (paired Wilcoxon
test: LASSO vs Elastic Net, P = 0.001; LASSO vs random forest, P = 1e−08; Elastic Net vs random
forest, P = 4e−14)
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of possible workflow configurations in order to arrive at recommendations about sens-
ible default parameters. To test the influence of different parameter choices within the
complete data analysis pipeline, we performed an ANOVA analysis to quantify their
relative importance on the resulting classification accuracy (Fig. 4d and the “Methods”
section). Whereas the choice of filtering method and feature selection regime has little
influence on the results, the normalization method and ML algorithm explained more
of the observed variance in classification accuracy. Analysis of the different
normalization methods shows that most of the differences can be explained by a drop
in performance for naively normalized data (only total sum scaling and no further
normalization) in combination with LASSO or Elastic Net logistic regression (Add-
itional file 1: Figure S8). In contrast, the random forest classifier depended much less
on optimal data normalization. Lastly, we compared the best classification accuracy for
each classification task across the different ML algorithms. Interestingly, in contrast to
a previous report [19], this analysis indicates that on average Elastic Net logistic regres-
sion outperforms LASSO and random forest classifiers when considering the optimal
choice of ML algorithm (P = 0.001 comparing Elastic Net to LASSO and P = 4 × 10−14
comparing it to random forest, Fig. 4e). In summary, this large-scale analysis demon-
strates the versatility of the ML workflows provided by SIAMCAT and validates its
default parameters as well as the robustness of classification accuracy to deviations
from these.
Cross-study evaluation of microbiome signatures is crucial to establish their validity
across patient populations. However, such comparisons are potentially hindered by
inter-study differences in sample handling and data generation, with technical variation
observed to often dominate over biological factors of interest [88–90]. Additionally,
biological and clinical factors can contribute to inter-study differences. These not only
include influences of geography, ethnicity, demographics, and lifestyle, but also how
clinical phenotypes are defined and controls selected for each study [91].
Up to now, it has not been systematically explored how well microbiome-based ML
models transfer across a range of diseases. To close this gap, we used our large-scale
ML meta-analysis and trained ML models for each task using mOTUs2 taxonomic pro-
files as input (based on the previously established best-performing parameter set). We
subsequently focused on models with reasonable cross-validation accuracy (AUROC > 0.75)
and applied these to all remaining datasets to make predictions.
Cross-study application of ML models is straightforward within the same disease,
since the model predictions on external datasets can easily be evaluated by an AUROC
(Additional file 1: Figure S9, [37, 38]) under the assumption that case and control defi-
nitions are comparable between studies. However, when applying an ML model to a
dataset from another disease, ROC analysis cannot be directly applied, since the cases
the model was originally trained to detect are from another disease than those of the
evaluation dataset. For this cross-disease application of ML models, we conducted ex-
tended evaluations, which specifically addressed the following two questions (see Add-
itional file 1: Figure S10 and the “Methods” section). First, we asked to which extent
the separation between cases and controls (in terms of prediction scores) would be
maintained when control samples of a different study are used. We therefore employed
a modified ROC analysis (comparing true-positive rates from cross-validation to exter-
nal FPRs via AUROC) as a newly defined measure of cross-study portability of an ML
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model. For convenience, we rescaled it to range between 0 (indicating a complete loss
of discriminatory power on external data) and 1 (meaning that the ML model could be
transferred to another dataset without loss of discrimination accuracy). Second, we
asked how specific an ML model would be to the disease it was trained to recognize, or
whether its FPR would be elevated when presented with cases from a distinct condition.
This is of interest in the context of an ongoing debate on whether there is a general
gut microbial dysbiosis or distinct compositional changes associated with each disease
[19, 20, 92]. Disease-specific classifiers would also be of clinical relevance when applied
to a general population: due to large differences in disease prevalence, a model for CRC
(a condition with low prevalence) misclassifying many type 2 diabetes (T2D) patients
(high prevalence) would in the general population detect many more (false) T2D cases
than true CRC cases, and thus have very low precision. To quantify the prediction rate
for other diseases of an ML model, i.e., its disease specificity, we assessed how many
samples from a distinct disease would be mispredicted as positive for the disease the
ML model was trained on at a cutoff adjusted to maintain a FPR of 10% on the cross-
validation set.
These extended evaluations showed low cross-study portability on the majority of
external datasets (apparent also from a more than twofold increase in false posi-
tives on average) for most models (Additional file 1: Figure S11). Similarly, (false-
positive) predictions for other diseases were elevated for most models (by a factor
of 2.8 on average), with the extreme case of the ankylosing spondylitis (AS) model
predicting more than 90% of cases from other diseases to be AS positive (median
across studies, Additional file 1: Figure S12). These evaluations indicate that naive
ML model transfer is substantially impacted—if not rendered impossible—by bio-
logical and technical study heterogeneity, apparent from loss of general accuracy
and disease specificity.
In order to improve the cross-study portability of ML models, we devised a strategy
we call control augmentation, in which randomly selected control samples from inde-
pendent microbiome population cohort studies [93–95] are added to the training set
during model fitting (Fig. 5a, see the “Methods” section). This was motivated by the hy-
pothesis that additional variability from a greater control pool comprising hetero-
geneous samples from multiple studies would enable classifiers to more specifically
recognize disease signals while at the same time minimizing overfitting on peculiarities
of a single dataset. However, a theoretical limitation of this approach is that the defin-
ition of controls can vary greatly across studies. In spite of this, in practice, we found
control augmentation to greatly enhance cross-study portability uniformly across all
ML models, both in cross-study analysis within the same condition and across different
diseases (Fig. 5b, c, Additional file 1: Figure S9, S11). At the same time, cross-disease
predictions decreased (Fig. 5c, d, Additional file 1: Figure S12) implying that it is an
effective strategy to increase disease specificity of ML models.
The control augmentation strategy did not strongly depend on the set of controls
used. We found large (> 250 samples) cohort studies to work well as a pool for control
augmentation (allowing us to add five times the amount of control samples to each
dataset). However, augmentation with fewer controls or with other datasets improved
cross-study portability and disease specificity to almost the same effect (Additional file
1: Figure S13).
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With cross-study portability greatly improved, we expect the remaining cross-disease
predictions to be largely due to biological similarities between diseases rather than due
to technical influences. In support of this, we show that CRC signatures have a ten-
dency to cross-predict samples from patients with intestinal adenomas (ADA) or in-
flammatory bowel disease (CD), both of which are risk factors for CRC development
[96]. Similarly, UC models cross-predict CD cases and vice versa, reflecting more gen-
eral gut microbial changes, i.e., loss of beneficial commensal bacteria, that are shared
across both types of inflammatory bowel disease [97]. In summary, we demonstrate that
control augmentation is an effective strategy to broadly enable the validation of micro-
biome disease signatures across different studies, since it can overcome study-specific
biases, which preclude the naive transfer of ML models.
When comparing microbiome signatures across diseases in more detail, we also revis-
ited the question of whether microbiome alterations are specific to a disease, or signs
of a general dysbiotic state [20]. As many ML algorithms, in particular (general-
ized) linear models, such as LASSO or Elastic Net logistic regression models,
allow for model introspection, microbiome biomarkers can easily be extracted
and their weight in the model directly quantified by (normalized) coefficient
values. The model weights of the control-augmented models showed a clear clus-
tering by disease in principal coordinate space revealing broad disease similarity
patterns in terms of microbiome predictors that may reflect etiological similarities
(Fig. 5e, not apparent from naively transferred ML models, Additional file 1: Fig-
ure S14). To obtain a more nuanced view of the gut bacterial taxa underlying
these disease similarities, we analyzed individual mOTUs (grouped by genus
membership) that were selected as predictors in disease models (Fig. 5f, to
minimize bias from multiple studies of the same disease, we used the mean
model for each disease and extracted those features whose weights accounted for
more than 50% of the model, see the “Methods” section for details). We found
some disease-enriched predictors to be very specific for a single disease, such as
Veillonella spp. for LIV, Bifidobacteria and Neisseria mOTUs for AS, or Gemella
and Parvimonas mOTUs for CRC. In contrast, species from other genera, for ex-
ample, Lactobacillus, Bacteroides, or Fusobacteria, appear predictive of several
diseases, although species and subspecies belonging to these vary in terms of
their disease specificity (Additional file 1: Figure S15). Regarding control-enriched
predictors, species from some genera are frequently depleted across multiple dis-
eases (Anaerostipes and Romboutisa) while some diseases are marked by broad
depletion of beneficial microbes, e.g., CD (consistent with [97]).
Overall, enabled by control augmentation as an effective strategy to improve
cross-study portability of ML models, our cross-disease meta-analysis reveals both
shared and disease-specific predictors as a basis for further development of
microbiome-based diagnostic biomarkers.
Meta-analysis of Crohn’s disease gut microbiome studies
Microbiome disease associations being reported at an ever-increasing pace have also
provided opportunities for comparisons across multiple studies of the same disease to
assess the robustness of associations and the generalizability of ML models [19, 20, 37,
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Fig. 5 Control augmentation improves ML model disease specificity and reveals shared and distinct
predictors. a Schematic of the control augmentation procedure: control samples from external cohort
studies are added to the individual cross-validation folds during model training. Trained models are applied
to external studies (either of a different or the same disease) to determine cross-study portability (defined
as maintenance of type I error control on external control samples) and cross-disease predictions (i.e., false
detection of samples from a different disease). b Cross-study portability was compared between naive and
control-augmented models showing consistent improvements due to control augmentation. c Boxplots
depicting cross-study portability (left) and prediction rate for other diseases (right) of naive and control-
augmented models (see Fig. 1 for the definition of boxplots). d Heatmap showing prediction rates for other
diseases (red color scheme) and for the same disease (green color scheme) for control-augmented models
on all external datasets. True-positive rates of the models from cross-validation on the original study are
indicated by boxes around the tile. Prediction rates over 10% are labeled. e Principal coordinate (PCo)
analysis between models based on Canberra distance on model weights. Diamonds represent the mean
per dataset in PCo space across cross-validation splits, and lines show the standard deviation. f Visualization
of the main selected model weights (predictors corresponding to mOTUs, see the “Methods” section for the
definition of cutoffs) by genus and disease. Absolute model weights are shown as a dot plot on top,
grouped by genus (including only genera with unambiguous NCBI taxonomy annotation). Below, the
number of selected weights per genus is shown as a bar graph, colored by disease (see e for color key).
Genus labels at the bottom include the number of mOTUs with at least one selected weight followed by
the number of mOTUs in the complete model weight matrix belonging to the respective genus
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38]. To demonstrate SIAMCAT’s utility in single-disease meta-analyses, we analyzed
five metagenomic datasets [5, 27–30], all of which included samples from patients with
Crohn’s disease (CD) as well as controls not suffering from inflammatory bowel dis-
eases (IBD). Raw sequencing data were consistently processed to obtain genus abun-
dance profiles with mOTUs2 [85].
Based on SIAMCAT’s check.associations function, we identified microbial genera that
are significantly associated with CD in each study and visualized their agreement across
studies (Fig. 6a, left panel). In line with previous findings [4], the gut microbiome of
CD patients is characterized by a loss of diversity and many beneficial taxa. Though
our re-analysis of the data from [30] could not identify any statistically significant
genus-level associations, possibly due to the relatively small number of individuals or
the choice of control samples obtained from patients with non-IBD gastrointestinal
symptoms, the other four studies showed remarkable consistency among the taxa lost
in CD patients, in particular, for members of the Clostridiales order.
We further investigated variation due to technical and biological differences between
studies as a potential confounder using SIAMCAT’s check.confounder function follow-
ing a previously validated approach [37]. For many genera, variation can largely be at-
tributed to heterogeneity among studies; the top five associated genera (cf. Figure 6a),
however, vary much more with disease status, suggesting that their association with CD
is only minimally confounded by differences between studies (Fig. 6b).
Next, we systematically assessed cross-study generalization of ML models trained to
distinguish CD patients from controls using SIAMCAT workflows. To this end, we
trained an Elastic Net model for each study independently and evaluated the perform-
ance of the trained models on the other datasets (Fig. 6c and the “Methods” section).
Most models maintained very high classification accuracy when applied to the other
datasets for external validation (AUROC > 0.9 in most cases); again with the exception
of the model cross-validated on the data from [30], which exhibited substantially lower
accuracy in both cross-validation and external validation.
We lastly assessed the importance of individual microbial predictors in the CD
models. The LASSO, and to some extent also the Elastic Net, are sparse models, in
which the number of influential predictors (with non-zero coefficients) is kept small.
As a consequence, these ML methods tend to omit statistically significant features
when they are correlated to each other in favor of a smaller subset of features with op-
timal predictive power. Nonetheless, in our meta-analysis of CD, the feature weights
derived from multivariable modeling corresponded well to the univariate associations,
and also showed some consistency across the four studies in which clear CD associa-
tions could be detected and an accurate ML model trained (Fig. 6a, right panel). Taken
together, these results demonstrate that SIAMCAT could be a tool of broad utility for
consolidating microbiome-disease associations and biomarker discovery by leveraging a
large amount of metagenomic data becoming available for ML-based analyses.
Discussion
The rising interest in clinical microbiome studies and microbiome-derived diagnostic,
prognostic, and therapeutic biomarkers also calls for more robust analysis procedures.
An important step in that direction is the development of freely available, comprehen-
sive, and extensively validated analysis workflows that make complex ML procedures
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available to non-experts, ideally while safeguarding against statistical analysis pitfalls.
Designed with these objectives in mind, SIAMCAT provides a modular analysis frame-
work that builds on the existing R-based microbiome analysis environment: data inte-
gration from DADA2 [98] or phyloseq [69] is straightforward since SIAMCAT
internally uses the phyloseq object. ML algorithms and procedures in SIAMCAT inter-
face to the mlr package [70], a general-purpose ML library. Since the multitude of ML
algorithms, workflow options, and design choices within such a general package can
make ML workflow design challenging for non-experts, SIAMCAT mainly aims to en-
able users to apply robust and validated ML workflows to their data with preprocessing
and normalization options tailored to the characteristics of microbiome data. At the
same time, SIAMCAT allows advanced users to flexibly set up and customize more
complex ML procedures, including non-standard cross-validation splits for dependent
measurements and supervised feature selection methods that are properly nested into
cross-validation (Fig. 3). Further developments of the package are planned to
Fig. 6 Meta-analysis of CD studies based on fecal shotgun metagenomic data. a Genus-level univariate and
multivariable associations with CD across the five included metagenomic studies. The heatmap on the left
side shows the generalized fold change for genera with a single-feature AUROC higher than 0.75 or smaller
than 0.25 in at least one of the studies. Associations with a false discovery rate (FDR) below 0.1 are
highlighted by a star. Statistical significance was tested using a Wilcoxon test and corrected for multiple
testing using the Benjamini-Hochberg procedure. Genera are ordered according to the mean fold change
across studies, and genera belonging to the Clostridiales order are highlighted by gray boxes. The right side
displays the median model weights for the same genera derived from Elastic Net models trained on the
five different studies. For each dataset, the top 20 features (regarding their absolute weight) are indicated
by their rank. b Variance explained by disease status (CD vs controls) is plotted against the variance
explained by differences between studies for individual genera. The dot size is proportional to the mean
abundance, and genera included in a are highlighted in red or blue. c Classification accuracy as measured
by AUROC is shown as a heatmap for Elastic Net models trained on genus-level abundances to distinguish
controls from CD cases. The diagonal displays values resulting from cross-validation (when the test and
training set are the same), and off-diagonal boxes show the results from the study-to-study transfer
of models
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accommodate the rapidly changing needs of the microbiome research community, and
updates will be published in accordance with the established Bioconductor release
schedule.
To showcase the power of ML workflows implemented in SIAMCAT, we performed
a meta-analysis of human gut metagenomic studies at a considerably larger scale than
previous efforts [17–22] (see Fig. 4). It importantly encompassed a large number of dis-
eases as well as different taxonomic and functional profiles as input that were derived
from different metagenomic sequencing techniques (16S rRNA gene and shotgun meta-
genomics sequencing) and profiling tools. Consequently, these benchmarks are ex-
pected to yield much more robust and general results than those from previous studies
[17–22]. In our exploration of more than 7000 different parameter combinations per
classification task (see the “Methods” section), we found the Elastic Net logistic regres-
sion algorithm to yield the highest cross-validation accuracies on average, albeit requir-
ing the input data to be appropriately normalized (see Fig. 4 and Additional file 1:
Figure S8). Compared with the choice of normalization method and classification algo-
rithm, other parameters had a considerably lower influence on the resulting classifica-
tion accuracy. SIAMCAT’s functionality to robustly fit statistical microbiome models
and evaluate their performance will enable comparison to established diagnostic bio-
markers [8] as an important prerequisite for further translation of microbiome research
into the clinic.
To help resolve the debate about spurious associations and reproducibility issues in
microbiome research [99], meta-analyses are crucial for the validation of microbiome
biomarkers [37, 38]. However, we found that ML models have substantial problems
with type I error control (> 2-fold increase in FPR) and disease specificity (> 2.5-fold el-
evated FPR) when naively transferred across studies. We propose measures to detect
these issues, which, if more widely adopted, could help to more precisely characterize
them and their underlying causes. To address them, we introduce the control augmen-
tation strategy, which greatly improved the cross-study portability of ML models. Being
the first attempt to overcome study heterogeneity for improved cross-study model ap-
plication, our work will hopefully stimulate further developments, which could easily be
evaluated on the provided datasets. However, all such ML meta-analyses are limited by
biological and clinical differences between studies [91], which will have to be addressed
by better reporting standards [100]. Within these limitations, our ML meta-
analysis datasets could become a valuable community resource for method devel-
opment, systematic assessment of disease similarities, and further exploration of
globally applicable microbiome biomarkers including validation of their disease
specificity.
Using model introspection after control augmentation, we could revisit the question
if microbiome alterations are specific to a given disease or more general hallmarks of
dysbiosis [20]. In general, we found depletion of beneficial bacteria to be more often
shared across several diseases (e.g., Anaerostipes or Romboutisa), in particular, in the
subtypes of IBD. Conversely, disease-enriched bacteria were more often specific to a
given disease. This could mean that some disease-specific microbiome alterations may
reflect pathogens or pathobionts acting either as etiological agents or exploiting specific
disease-related changes in the intestinal milieu. As examples of disease-specific
markers, Parvimonas spp. are predictive for colorectal cancer, which is consistent with
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mechanistic work demonstrating this species to accelerate proliferation and cancer de-
velopment both in vitro and in vivo [101]. Similarly, a putative link between oral
Veillonella spp. and liver cirrhosis severity has been reported in the context of proton-
pump inhibitor therapy [102], potentially enabled by increased transmission from the
oral to the gut microbiome [78]. Other taxa showing a broader disease spectrum, such
as Fusobacterium spp., have been extensively studied both in the context of CRC [103]
and in IBD [104] using cellular and animal models. However, firmly establishing
disease specificity or disease spectra for microbial biomarkers will be difficult to
achieve in preclinical studies but require large patient cohorts. Nonetheless, our
analyses generated candidates of both shared and disease-specific gut microbial bio-
markers to guide further investigations of specific hypotheses on their ecological
roles.
Although the analyses presented here are focused on human gut metage-
nomic datasets with disease prediction tasks, SIAMCAT is not restricted to
these. It can also be applied to other tasks of interest in microbiome research,
e.g., for investigating the effects of medication (see Additional file 1: Figure
S2). Metagenomic or metatranscriptomic data from environmental samples can
also be analyzed using SIAMCAT, e.g., to understand the associations between
community composition and transcriptional activity of the ocean microbiome
with physicochemical environmental properties (see Additional file 1: Figure S16 for




SIAMCAT is implemented as an R package with a modular architecture, allow-
ing for a flexible combination of different functions to build ML and statistical
analysis workflows (see the “Code box” section). The output of the functions
(for example, the feature matrix after normalization) is stored in the SIAMCAT
object, which is an extension of the phyloseq object that contains the raw fea-
ture abundances, meta-variables about the samples, and other optional informa-
tion (for example, a taxonomy table or a phylogenetic tree) [69]. The label
defining the sample groups for comparison is then derived from a user-specified
meta-variable or an additional vector. ML models are trained using the mlr
infrastructure as an interface to the implementations of different ML algorithms
in other R packages [70]. SIAMCAT is available under the GNU General Public
License, version 3.
Code box
Given two R objects called feat (relative abundance matrix) and meta (meta-
variables about samples as a dataframe, containing a column called disease
which encodes the label), the entire analysis can be conducted with a few com-
mands (more extensive documentation can be found online in the SIAMCAT vi-
gnettes).
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Included datasets and microbiome profiling
In this study, we analyzed taxonomic and functional profiles derived with different pro-
filing tools from several metagenomic datasets (see Additional file 2: Table S1). Taxo-
nomic profiles generated using the RDP classifier [83] on the basis of 16S rRNA gene
sequencing data were downloaded from a recent meta-analysis by Duvallet et al. [20]
and summarized at the genus level. MetaPhlAn2 [84] and HUMAnN2 [86] taxonomic
and functional profiles were obtained from the curatedMetagenomicsData R package
[72] for all human gut datasets within the package that contained at least 20 cases and
20 controls. MetaPhlAn2 profiles were filtered to contain only species-level microbial
taxa.
Additional datasets were profiled in-house with the following pipeline implemented
in NGless [106]: after preprocessing with MOCAT2 [107] and filtering for human reads,
taxonomic profiles were generated using the mOTUsv2 profiler [85], and functional
profiles were calculated by first mapping reads against the integrated gene catalog [108]
and then aggregating the results by eggNOG orthologous groups [87].
Additionally, genus-level taxonomic profiles from the TARA Oceans microbiome
project [105] were used for two different classification tasks: to classify samples from
polar and non-polar ocean regions and to classify samples based on their iron concen-
tration at a depth of 5 m (high vs low iron content).
Primary package outputs and confounder analysis
To illustrate the main outputs of SIAMCAT, we analyzed the taxonomic profiles from
a metagenomic study of IBD [27] included in the curatedMetagenomicsData R package
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[72]. For the analyses presented in Fig. 1, we restricted the dataset to control samples
from Spain and cases with UC, since the two IBD subtypes included in the dataset
(ulcerative colitis and Crohn’s disease) are very different from one another in terms of
the associated changes in the gut microbiome composition (see the SIAMCAT
vignettes for more information or the “Code box” section for an outline of the basic
SIAMCAT workflow.
To demonstrate how SIAMCAT can aid in confounder detection, we used the same
dataset but this time included the Danish control samples in order to explore potential
confounding by differences between samples collected and processed in these two
countries. The analyses presented in Fig. 2 have all been conducted with the respective
functions of SIAMCAT (see SIAMCAT vignettes).
Machine learning hyperparameter exploration
To explore suitable hyperparameter combinations for ML workflows, we trained an ML
model for each classification task and each hyperparameter combination. By hyperpara-
meter, we mean configuration parameters of the workflow, such as normalization parame-
ters, tuning parameters controlling regularization strength, or properties of the external
feature selection procedure in contrast to model parameters fitted during the actual training
of the ML algorithms. Specifically, we varied the filtering method (no data filtering; preva-
lence filtering with 1%, 5%, 10% cutoffs; abundance filtering with 0.001, 0.0001, and 0.0001
as cutoffs; and a combination of abundance and prevalence filtering), the normalization
method (no normalization beyond the total sum scaling, log-transformation with
standardization, rank-transformation with standardization, and centered log-ratio trans-
formation), the ML algorithm (LASSO, Elastic Net, and random forest classifiers), and fea-
ture selection regimes (no feature selection and feature selection based on generalized fold
change or based on single-feature AUROC; cutoffs were 25, 50, 100, 200, and 400 features
for taxonomic profiles and 100, 500, 1000, and 2000 features for functional profiles). To
cover the full hyperparameter space, we therefore trained 7488 models for taxonomic and
3168 models for functional datasets for each classification task.
To determine the optimal AUROC across input types (shown in Fig. 4), we calculated
for each individual parameter combination the mean AUROC across all classification
tasks with a specific type of input. Different feature filtering procedures could lead to
cases in which the feature selection cutoffs were larger than the number of available
features after filtering, therefore terminating the ML procedure. For that reason, we
only considered those parameter combinations that did produce a result for all classifi-
cation tasks with the specific type of input data.
To compare the importance of feature filtering, feature selection, normalization
method, and ML algorithm on classification accuracy, we trained one linear model per
classification task predicting the AUROC values from those variables. We then parti-
tioned the variance attributable to each of these variables by calculating type III sums
of squares using the Anova function from the car package in R [109].
In order to contrast the class separation of samples in distance space with the classifi-
cation performance achieved by ML algorithms (see Additional file 1: Figure S6), we
designed a distance-based measure of separation. For each dataset, we determined the
distances between all pairs of samples within a class as well as all pairs of samples
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between classes and then calculated an AUROC value based on these two distributions.
This distance-based measure effectively quantifies to what extent samples are closest to
other samples from the same class (i.e., cluster together) and hence corresponds well to
the visual separation of classes in ordination space (see Additional file 1: Figure S6).
Model transfer, cross-study portability, and prediction rate for other diseases
To assess cross-study portability and prediction rate for other diseases, ML models
were applied to external datasets using the make.predictions function in SIAMCAT. In
short, the function uses the normalization parameters of the discovery dataset to
normalize the external data in a comparable way and then makes predictions by
averaging the results of the application of all models of the repeated cross-validation
folds to the normalized external data.
Cross-study portability is then calculated by comparing the predictions for cases in
the discovery datasets and controls in the external dataset. First, the AUROC between
these two prediction vectors is calculated, and values below 0.5 (when the predictions
on controls in the external dataset are higher than predictions on cases in the discovery
dataset) are set to 0.5. Cross-study portability is then defined as (|0.5 - AUROC|)*2 so
that it afterwards ranges from 0 (no separation between cases and external controls or
higher predictions on external controls) to 1 (perfect separation between cases and
external controls).
To calculate the prediction rate for other diseases (or the same disease) on external
datasets, a cutoff on the (real-valued) predictions is chosen so that the FPR in the dis-
covery dataset is 0.1. Based on this cutoff, the external predictions are evaluated as
positive (diseased) or negative predictions, and a detection rate corresponding to the
fraction of positive predictions is determined.
Training Elastic Net models with control augmentation
To train models with the control augmentation strategy, we used the data from cohort
microbiome studies as additional control samples [93–95]. Repeated measurements for
the same individual were removed in the case of Zeevi et al. [93]. For each training set
in the repeated cross-validation, we increased the number of control samples 5-fold by
randomly sampling the appropriate number of controls (in a balanced manner between
datasets to avoid overrepresentation of the larger external cohorts). Before addition, the
additional control samples were normalized using the normalization parameters of the
discovery set. Due to the introduction of additional variability, the control-augmented
Elastic Net models were trained with a pre-set alpha value of 0.5 to ensure the stability
of the model size.
To compare the predictors across different diseases, model weights of the control-
augmented models were transformed into relative weights by dividing by the sum of
absolute coefficient values. Then, models from the same disease were averaged. Predic-
tors (that is, mOTUs) were selected for display in Fig. 5f, if they (i) cumulatively con-
tributed more than 50% of the mean relative disease model, (ii) their individual weights
were bigger than 1%, and (iii) the genus annotation had an unambiguous NCBI
taxonomy.
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Illustration of common pitfalls in machine learning procedures
To demonstrate how naive sequential application of supervised feature selection and
cross-validation might bias performance estimations, we trained LASSO ML models to
distinguish colorectal cancer cases from controls based on MetaPhlAn2-derived species
abundance profiles using the dataset with the handle ThomasAM_2018a [38] obtained
through the curatedMetagenomicsData R package [72]. For the incorrect procedure of
feature selection, single-feature AUROC values were calculated using the complete
dataset (inverted for negatively associated features). Then, the features with the highest
AUROC values were selected for model training (number depending on the cutoff). In
contrast, the correct procedure implemented in SIAMCAT excludes the data in the test
fold when calculating single-feature AUROC values; instead, AUROC values are calcu-
lated on the training fold only. To test generalization to external data, the models were
then applied to another colorectal cancer metagenomic study [8] available through the
curatedMetagenomicsData R package (also see the SIAMCAT vignette: holdout testing).
To illustrate the problem arising when combining naive cross-validation with
dependent data, we used the Crohn’s disease (CD) datasets used in the meta-analysis
described below. We first subsampled the iHMP dataset [30] to five repeated measure-
ments per subject, as some subjects had been sampled only five times and others more
than 20 times. Then, we trained LASSO models using both a naive cross-validation and
a cross-validation procedure in which samples from the same individual were always
kept together in the same fold. External generalization was tested on the other four CD
datasets described below.
Meta-analysis of Crohn’s disease metagenomic studies
For the meta-analysis of Crohn’s disease gut microbiome studies, we included five
metagenomic datasets [5, 27–30] that had been profiled with the mOTUs2 profiler [85]
on the genus level. While some datasets contained both UC and CD patients [5, 27,
30], other datasets contained only CD cases [28, 29]. Therefore, we restricted all
datasets to a comparison between only CD cases and control samples, since the two
subtypes of IBD are very different from each other.
For training of ML models, we blocked repeated measurements for the same individ-
ual when applicable [27, 28, 30]; specifically for the iHMP dataset [30], we also sub-
sampled the dataset to five repeated measurements per individual to avoid biases
associated with differences in the number of samples per individual. For external
validation testing, we completely removed repeated measurements in order not to bias
the estimation of classification accuracy.
To compute association metrics and to train and evaluate ML models, each dataset
was encapsulated in an individual SIAMCAT object. To produce the plot showing the
variance explained by label vs the variance explained by study, all data were combined
into a single SIAMCAT object. The code to reproduce the analysis can be found in the
SIAMCAT vignettes.
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